Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine added to long-acting methylphenidate for executive dysfunction in adolescents with ADHD
IRCT20250917067279N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Memantine + long-acting methylphenidate with Placebo + long-acting methylphenidate (2 arms). Primary endpoints: Total score on the self-report scale of attention deficit hyperactivity disorder (ASRS), Severity of executive dysfunction and 1 more. Started Oct 2025; status: completed.
02
Drugs
memantinemethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20250917067279N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250917067279N1.